Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 12/20 | 1.00 |
| ▸ | STAT1 | P42224 | 1/20 | 0.87 |
| ▸ | STAT4 | Q14765 | 1/20 | 0.87 |
| ▸ | XIAP | P98170 | 6/20 | 0.40 |
| ▸ | BIRC3 | Q13489 | 6/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 6/20 | 0.40 |
| ▸ | STAT5A | P42229 | 2/20 | 0.37 |
| ▸ | STAT5B | P51692 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22468641 | 1.00 | STAT3 (1.00) | STAT3STAT1STAT4XIAPBIRC3 | |
| SCHEMBL22468640 | 1.00 | STAT3 (1.00) | STAT3STAT1STAT4XIAPBIRC3 | |
| SCHEMBL23860035 | 0.96 | STAT3 (0.92) | STAT3STAT1STAT4XIAPBIRC3 | |
| SCHEMBL23860038 | 0.96 | STAT3 (0.92) | STAT3STAT1STAT4XIAPBIRC3 | |
| SCHEMBL30308451 | 0.96 | STAT3 (0.92) | STAT3STAT1STAT4XIAPBIRC3 | |
| SCHEMBL25218828 | 0.95 | STAT3 (0.91) | STAT3STAT1STAT4XIAPBIRC3 | |
| SCHEMBL25218829 | 0.95 | STAT3 (0.91) | STAT3STAT1STAT4XIAPBIRC3 | |
| SCHEMBL30308675 | 0.95 | STAT3 (0.91) | STAT3STAT1STAT4XIAPBIRC3 | |
| SCHEMBL22525399 | 0.93 | STAT3 (0.88) | STAT3STAT1STAT4XIAPBIRC3 | |
| SCHEMBL25228341 | 0.93 | STAT3 (0.88) | STAT3STAT1STAT4XIAPBIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-20230083015-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | UNIV MICHIGAN REGENTS (US) | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230083015-A1 | SMALL MOLECULE DEGRADERS OF STAT3 | STAT1, STAT3, JAK2 | STAT3 2/4885STAT1 1/4885STAT4 6/4885 |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | HLA-DRB1, CD74, HLA-C | STAT3 2125/4885STAT1 893/4885STAT4 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.